Illinois Municipal Retirement Fund Has $12.06 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Illinois Municipal Retirement Fund grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 9.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 195,297 shares of the medical equipment provider’s stock after purchasing an additional 17,664 shares during the quarter. Illinois Municipal Retirement Fund owned about 0.09% of Hologic worth $12,063,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the period. Dark Forest Capital Management LP grew its stake in shares of Hologic by 7.9% in the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider’s stock worth $220,000 after acquiring an additional 223 shares during the last quarter. Baker Avenue Asset Management LP grew its stake in shares of Hologic by 0.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider’s stock worth $3,031,000 after acquiring an additional 225 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Finally, Integrated Advisors Network LLC grew its stake in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after acquiring an additional 289 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOLX has been the topic of several research analyst reports. Evercore ISI lowered their price objective on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating on the stock in a research note on Friday, May 2nd. Raymond James Financial restated an “outperform” rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $77.42.

Hologic Stock Down 0.2%

NASDAQ HOLX opened at $65.01 on Friday. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock’s 50 day moving average is $60.00 and its two-hundred day moving average is $64.06. The company has a market capitalization of $14.49 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 2.39 and a beta of 0.55. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.03 earnings per share. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company’s stock, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.